ATIC

ATIC are delighted to welcome Professor David O'Neal to present on novel approaches to metabolic control in diabetes at our next Beyond Insulin seminar. See details below:
Date: Friday 26th June; 1pm – 2pm AEST
Speaker: Prof David O'Neal, The University of Melbourne
Title: Novel approaches to metabolic control in diabetes: multianalyte sensing and gene therapy
For more information and to register please visit: https://atic.svi.edu.au/news-events/novel-approaches-to-metabolic-control-in-diabetes-multianalyte-sensing-and-gene-therapy/
We look forward to seeing you there.t.r.g_au

Novel Approaches To Metabolic Control In Diabetes: Multianalyte Sensing And Gene Therapy | ATIC Seminar 32, Beyond Insulin Seminar Series - Professor David O'Neal presents novel approaches to metabolic control in diabetes.

Last Sunday, Professor John Wentworth spoke with Dr Ross Walker on the Healthy Living program across 2GB, 3AW, 4BC and 6PR radio stations. They discussed the recent approval of TZield and the importance of screening for type 1 diabetes. You can find out more about screening for type 1 diabetes via Type1Screen and you can visit our ATIC website for information about the clinical trials that John and Ross speak about.

Potential delay of the onset of clinical Type 1 diabetes - Healthy Living Dr Ross Walker speaks with Professor John Wentworth, Endocrinologist and Senior Clinical Research Fellow at St Vincent's Institute of Medical Research. We discuss the TGA’s historic registration of Tzield, the very first non-insulin medicine designed to delay the onset of clinical Type 1 diabetes....

UPDATE:
The SAFEGUARD study is now available in more locations around Australia and New Zealand!
If you have been diagnosed with type 1 diabetes in the last 100 days and are interested in being involved in a clinical trial of a new medicine that is hoped to protect the body's ability to make insulin, please reach out via the details in the image or visit our website at atic.svi.edu.au/clinicaltrials/

UPDATE!
We are now able to offer the MT-101-101 study in Queensland and Victoria. If you are an adult with type 1 diabetes and are interested in taking part in research for a new treatment, please contact us via the details in the image or visit our website atic.svi.edu.au/clinicaltrials

Tzield is approved for use in Australia for people with stage 2 type 1 diabetes.
But how do you find out if you have stage 2 type 1 diabetes?
The first step is to find out if you have type 1 diabetes related autoantibodies. These autoantibodies can be detected on a simple screening blood test. offers free autoantibody screening to all people in Australia who have a family member with type 1 diabetes and areover 2 years old. The test is simple and can be done in the comfort of your own home. For more information, visit their website at https://type1screen.org.

Following the approval of Tzield in Australia last week, we received a lot of questions about the stages of T1D. Our friends at Breakthrough T1D Australia have produced this wonderful image that explains the stages in detail. They also have more information available on their website at https://breakthrought1d.org.au/early-detection-of-type-1-diabetes/stages/

Do you have type 1 diabetes?
Are you keen to participate in research that may help to stop or reduce the immune system attack on the pancreas?
You can find out more about this clinical trial on our website at https://atic.svi.edu.au/clinical-trials/clinical-trials/ or reach out to our friendly team on [email protected]

It was fantastic to feel the excitement about the approval of Tzield for use in Australia yesterday!
For many people, this was the first time they’ve heard the term “immunotherapy” in relation to type 1 diabetes. So, what does it actually mean?
At ATIC, we’ve created a short video explaining:
• what immunotherapy is,
• how it works in type 1 diabetes,
• the stages of type 1 diabetes,
• and how research is changing the future of care
Watch the video here: https://atic.svi.edu.au/news-events/new-video-resource/
This approval marks an exciting new era moving from managing type 1 diabetes to potentially delaying disease progression itself.

ATIC is supported by Breakthrough T1D Australia
Animation by Diabetes UK

New ATIC Video Resource | ATIC The ATIC Community Engagement Panel has led the development of a new video resource designed to raise awareness among health professionals and the community about the benefits of immunotherapy for type 1 diabetes.

ATIC's own Prof John Wentworth spoke to Channel 9's Sarah Abo on Today this morning about the TGA approval of Tzield. You can share John's excitement here: https://youtu.be/jmW7nqkOxh8?si=WM6vXDQde1Gph2C8

life-changing diabetes drug approved for Australian use | 9 News Australia There's new hope this morning for diabetes patients, with a life-ch...

Sanofi share its wonderful news about Tzield approval in Australia. This post includes the link to the Consumer Medicine Information which includes more information about Tzield, its uses and important safety considerations.

A new therapy, Tzield® (teplizumab) is now registered in Australia for those with an early, pre-symptomatic stage of .

This immunotherapy is indicated to delay the onset of Stage 3 type 1 diabetes mellitus (T1D) in adult and paediatric patients aged 8 years and older with Stage 2 type 1 diabetes mellitus.

Tzield® (teplizumab) is not yet available on the PBS.

All medicines have side effects. The most frequently observed adverse events in patients receiving Tzield® include reductions in certain white blood cells and rash. Bacterial and viral infections, including cases of viral reactivation have been reported with Tzield®.

For more information about the medicine, including additional safety considerations, please see the Consumer Medicine Information > http://spkl.io/618876JOY